Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04902131
Other study ID # 000347
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 2, 2021
Est. completion date August 15, 2022

Study information

Verified date May 2022
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

MENOPUR is a human menotrophin product, with a combination of human follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. Human chorionic gonadotrophin (hCG) is the major contributor to the LH activity in the product. MENOPUR is approved in more than 130 countries for a variety of strengths and indications. In China, MENOPUR, 75 IU is approved for controlled ovarian hyperstimulation in relation to assisted reproductive technology (ART). The current trial is intended for supporting marketing authorization approval of a new formulation of MENOPUR in China. MENOPUR is currently available in China as a powder and solvent for solution for injection, containing 75 IU of FSH and 75 IU of LH activity. A new liquid formulation is developed by Ferring Pharmaceuticals for administration with a disposable pre-filled injection pen, containing 600 IU of FSH and 600 IU of LH activity. MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL is the test product and MENOPUR powder and solvent for solution for injection, 75 IU is the reference product in this trial.


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date August 15, 2022
Est. primary completion date August 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 40 Years
Eligibility Key Inclusion Criteria: - Chinese women between the ages of 21 to 40 years at the time of signing the informed consent form - Non-users or users of the combined oral contraceptive (COC) pill who describe experiencing menstrual cycles of 24 to 35 days in duration (both inclusive) - Healthy according to medical history, physical and gynecological examinations, vital signs, 12-lead electrocardiogram, and laboratory tests in blood and urine - Serum FSH levels =5 IU/L and estradiol levels =50 pg/mL on Day -3 and Day -1 in TP1 Key Exclusion Criteria: - Any finding at the gynecological examination, transvaginal ultrasound or by cervical smear that is considered medically important - A history of medical problems that could affect the functioning of the reproductive organs (ovaries and womb) - A history of any medical problems that may prevent use of the combined hormonal contraceptive pill

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL
Single dose cross-over bioequivalence trial
A MENOPUR powder including solvent for solution for injection, 75 IU
Single dose cross-over bioequivalence trial

Locations

Country Name City State
China Ferring investigational site Nanjing Gaoxin District
China Ferring investigational site Nanjing

Sponsors (1)

Lead Sponsor Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetic parameter of FSH: AUCt AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before investigational medicinal product [IMP] administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Primary Pharmacokinetic parameter of FSH: Cmax Cmax is defined as baseline adjusted maximum observed concentration. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of FSH: AUCinf AUCinf is defined as area under concentration-time curve from dosing to infinity using baseline adjusted concentrations. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of FSH: Tmax Tmax is defined as time of maximum observed concentration. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of FSH: CL/F CL/F is defined as apparent systemic clearance. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of FSH: Vz/F Vz/F is defined as apparent volume of distribution during terminal phase. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of FSH: ?z ?z is defined as first-order rate constant associated with the terminal (log-linear) portion of the concentration-time curve. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of FSH: t½ t½ is defined as terminal half-life. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of human chorionic gonadotrophin (hCG): AUCt AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of hCG: AUCinf AUCinf is defined as area under concentration-time curve from dosing to infinity using baseline adjusted concentrations. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of hCG: Cmax Cmax is defined as baseline adjusted maximum observed concentration. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and at 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 72, 96, 120, 168 and 216 hours after administration
Secondary Pharmacokinetic parameter of LH: AUCt AUCt is defined as area under the concentration-time curve from dosing to the last time point when the baseline adjusted concentration is above zero. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and 4, 8, 12, 24 and 48 hours after administration
Secondary Pharmacokinetic parameter of LH: Cmax Cmax is defined as baseline adjusted maximum observed concentration. At -1, -0.5 hours pre-dose, and immediately pre-dose (within 10 min before IMP administration), and 4, 8, 12, 24 and 48 hours after administration
Secondary Frequency of adverse events (AEs) stratified by intensity The frequency of subjects with total AEs and AEs by categories of intensity (mild, moderate, severe) are presented.
An AE was any untoward medical occurrence in a subject participating in clinical trial. The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activities); moderate = disruption of usual activities (disturbing); or severe = inability to work or perform usual activities (unacceptable).
From signing of the informed consent up to the end-of-trial (11 to 18 days after the last IMP administration)
Secondary Frequency of injection site reactions stratified by intensity The presence of injection site reactions (redness, pain, itching, swelling and bruising) immediately, 0.5 hours and 24 hours after the injection are presented.
The injection site reactions were assessed as none, mild, moderate and severe. The number of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.
Immediately after administration, and at 0.5 and 24 hours after administration on Day 1 and Day 2 of Treatment period 1 (TP1) and Time period 2 (TP2)
Secondary Change from baseline of vital signs (systolic and diastolic blood pressure) Vital signs comprising systolic and diastolic blood pressure will be presented. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of vital sign (pulse) Vital sign comprising pulse will be presented. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of vital sign (body temperature) Vital sign comprising body temperature will be presented. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of 12-lead electrocardiogram (ECG): Heart rate Change from baseline for 12-lead ECG (heart rate) parameter will be reported. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of 12-lead ECG: PR interval Change from baseline for 12-lead ECG (PR interval) parameter will be reported. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of 12-lead ECG: RR interval Change from baseline for 12-lead ECG (RR interval) parameter will be reported. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of 12-lead ECG: QRS interval Change from baseline for 12-lead ECG (QRS interval) parameter will be reported. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of 12-lead ECG: QT interval Change from baseline for 12-lead ECG (QT interval) parameter will be reported. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of 12-lead ECG: QTc interval Change from baseline for 12-lead ECG (QTc interval) parameter will be reported. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of 12-lead ECG: QRS axis Change from baseline for 12-lead ECG (QRS axis) parameter will be reported. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase Blood samples were collected for the analysis of clinical chemistry parameters including: Alanine aminotransferase, Alkaline phosphatase, Aspartate aminotransferase, and Gamma glutamyl transferase. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Albumin Blood samples were collected for the analysis of clinical chemistry parameter including: Albumin. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Glucose Blood samples were collected for the analysis of clinical chemistry parameter including: Glucose. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Calcium Blood samples were collected for the analysis of clinical chemistry parameter including: Calcium. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Chloride Blood samples were collected for the analysis of clinical chemistry parameter including: Chloride. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Cholesterol Blood samples were collected for the analysis of clinical chemistry parameter including: Cholesterol. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Phosphate Blood samples were collected for the analysis of clinical chemistry parameter including: Phosphate. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Potassium Blood samples were collected for the analysis of clinical chemistry parameter including: Potassium. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Sodium Blood samples were collected for the analysis of clinical chemistry parameter including: Sodium. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Urea (blood urea nitrogen) Blood samples were collected for the analysis of clinical chemistry parameter including: Urea (blood urea nitrogen). On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: C-reactive protein Blood samples were collected for the analysis of clinical chemistry parameter including: C-reactive protein. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Creatinine, Total bilirubin Blood samples were collected for the analysis of clinical chemistry parameters including: Creatinine, Total bilirubin. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Thyroid stimulating hormone Blood samples were collected for the analysis of clinical chemistry parameter including: Thyroid stimulating hormone. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Free triiodothyronine Blood samples were collected for the analysis of clinical chemistry parameter including: Free triiodothyronine. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Free thyroxine Blood samples were collected for the analysis of clinical chemistry parameter including: Free thyroxine. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: FSH Blood samples were collected for the analysis of clinical chemistry parameter including: FSH. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of clinical chemistry: Estradiol Blood samples were collected for the analysis of clinical chemistry parameter including: Estradiol. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Haematocrit Blood samples were collected for the analysis of haematology parameter including: Haematocrit. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Haemoglobin Blood samples were collected for the analysis of haematology parameter including: Haemoglobin. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Mean cellular volume Blood samples were collected for the analysis of haematology parameter including: Mean cellular volume. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Mean corpuscular haemoglobin content Blood samples were collected for the analysis of haematology parameter including: Mean corpuscular haemoglobin content. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Mean corpuscular haemoglobin concentration Blood samples were collected for the analysis of haematology parameter including: Mean corpuscular haemoglobin concentration. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Red blood cell (RBC) count Blood samples were collected for the analysis of haematology parameter including: RBC count. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Platelet count Blood samples were collected for the analysis of haematology parameter including: Platelet count. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: Reticulocytes Blood samples were collected for the analysis of haematology parameter including: Reticulocytes. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of haematology parameter: White blood cell count Blood samples were collected for the analysis of haematology parameter including: White blood cell count. On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Protein On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Glucose On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Bilirubin On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: pH and Specific Gravity On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Nitrite On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Ketone On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Urobilinogen On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Blood On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
Secondary Change from baseline of urinalysis parameter: Leukocytes On Day -1 in TP1 and TP2, and at the follow-up (end-of-trial, 11 to 18 days after the last IMP administration) visit. Baseline is defined as pre-administration (Day -1)
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer